Related Experiment Video
Updated: Mar 3, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
7α-acetoxy-6β-hydroxyroyleanone (Roy) modulates IL-6/STAT3/JAK2 mRNA expression and suppresses tumor growth in
Mariana Magalhães1,2,3,4, Renato Spigarelli5, Eva María Domínguez-Martín6,7
1PhD Programme in Experimental Biology and Biomedicine (PDBEB), Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal.
Introduction:
Glioblastoma (GB) is the most aggressive primary glioma, with a median survival of 15-18 months. Current treatments are often ineffective, largely due to tumor heterogeneity and recurrence. Advances in understanding GB's molecular landscape and microenvironment have highlighted new therapeutic strategies to fight this life-threatening tumor. Given the pivotal role of natural compounds in drug discovery, those with anti-inflammatory and cytotoxic/cytostatic properties are emerging as promising candidates for GB therapy.
Methods:
This study investigates the antitumor and immunomodulatory effects of 7α-acetoxy-6β-hydroxyroyleanone (Roy), a diterpene isolated by our team from Plectranthus hadiensis Schweinf., using both 2D and 3D GB cell models. U87 cells were used as a standard GB model and to generate monocellular and multicellular spheroids (U87, HMC3, and/or HBMEC cells). Both models were treated with 16 µM of Roy, a concentration previously shown to be tumor-specific.
Results:
Roy significantly reduced spheroid size and metabolic activity over time, with the most pronounced effects observed in multicellular spheroids. This compound also inhibited cell proliferation by preventing colony formation and downregulating CDK4 and VEGFA mRNA levels. Roy's bioactivity was enhanced in the presence of conditioned medium (secretome from GB and/or microglia cells), exerting a neuromodulatory effect by modulating IL6/JAK2/STAT3 mRNA expression and by suppressing the secretion of cytokines involved in the chronic inflammatory state within the GB microenvironment. Importantly, Roy was also able to cross the blood-brain barrier.
Conclusion:
These findings, in line with our previous work, underscore the cytotoxic potential of this natural compound, suggesting Roy as a promising lead candidate for future GB treatment strategies.
Insights
This study shows that 7α-acetoxy-6β-hydroxyroyleanone (Roy) effectively reduces glioblastoma (GB) growth and inflammation. This natural compound demonstrates potential as a novel therapeutic for this aggressive brain tumor.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Glioblastoma (GB) is an aggressive brain tumor with poor prognosis due to heterogeneity and recurrence.
- Current treatments for GB have limited efficacy.
- Natural compounds with anti-inflammatory and cytotoxic properties are promising for GB therapy.
Purpose of the Study:
- To investigate the antitumor and immunomodulatory effects of 7α-acetoxy-6β-hydroxyroyleanone (Roy) on glioblastoma.
- To evaluate Roy's efficacy in 2D and 3D glioblastoma cell models.
- To assess Roy's potential for crossing the blood-brain barrier.
Main Methods:
- Utilized 2D and 3D glioblastoma (GB) cell models, including monocellular and multicellular spheroids.
- Treated GB models with 16 µM of 7α-acetoxy-6β-hydroxyroyleanone (Roy).
- Assessed spheroid size, metabolic activity, cell proliferation, and gene/cytokine expression.
Main Results:
- Roy significantly reduced glioblastoma spheroid size and metabolic activity.
- Roy inhibited cell proliferation by downregulating CDK4 and VEGFA mRNA.
- Roy modulated IL6/JAK2/STAT3 expression and suppressed pro-inflammatory cytokines, demonstrating neuromodulatory effects and blood-brain barrier penetration.
Conclusions:
- 7α-acetoxy-6β-hydroxyroyleanone (Roy) exhibits significant cytotoxic and immunomodulatory potential against glioblastoma.
- Roy's ability to modulate the tumor microenvironment and cross the blood-brain barrier makes it a promising candidate for GB treatment.
- Further research into Roy as a lead compound for glioblastoma therapy is warranted.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:22MicroRNAs
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...